Compare Moderna, Inc. (MRNA) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Teradyne, Inc. — how do they compare? Moderna, Inc. trades at $136.95 (market cap $54.14B), while Teradyne, Inc. trades at $378 (market cap $59.99B). The key difference: Moderna, Inc. and Teradyne, Inc. are close in size by market cap, and Teradyne, Inc. pays a 0.14% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TER | |
|---|---|---|
Market Cap | $54.14B | $59.99B |
Sector | Health | Technology |
52-Week High | $174.38 | $483.84 |
52-Week Low | $22.36 | $112.24 |
Enterprise Value | $50.29B | $59.73B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Teradyne (TER) trades at $372.06, up 4.21% in the last session, with a bullish technical signal and strong institutional interest. The stock shows robust fundamentals, including a 59.24% gross margin and consistent earnings beats, with Q3 2026 EPS expected at $2.03. Recent news highlights AI-driven demand for UltraFLEXplus systems, positioning TER for growth in semiconductor testing.
Outlook is positive with a $474.78 analyst price target implying 28% upside, supported by AI and data center expansion. Risks include reliance on tech cycles and competitive pressures from KLA and Cohu. Cash flow trends show improvement, with net cash flow projected to turn positive in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
